ORLANDO (EGMN) - Researchers have identified four clinical risk factors that reduce the likelihood of achieving a 30%-or-greater decline in serum prostate-specific antigen during the 3 months after the start of chemotherapy, currently one of the most robust surrogates for overall survival in metastatic castration-resistant prostate cancer.Pretreatment visceral metastases (odds ratio, 0.63; P = .021), significant pain (OR, 0.66; P = .028), anemia (OR, 0.72; P = .069), and bone scan progression (OR,...